AI Market Mood: Stock Dashboard
ZBIO
Fundamental
Company: Zenas Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -3.90
Insider Own: 75.71%
Shs Outstand: 41.79M
Perf Week: 15.88%
Market Cap: 411.64M
Forward P/E: -
EPS next Y: -4.04
Insider Trans: 0.36%
Shs Float: 10.15M
Perf Month: 18.25%
Income: -156.99M
PEG: -
EPS next Q: -1.11
Inst Own: 32.34%
Short Float: 37.72%
Perf Quarter: 17.26%
Sales: 5.00M
P/S: 82.33
EPS this Y: 62.98%
Inst Trans: 18.47%
Short Ratio: 19.13
Perf Half Y: -54.10%
Book/sh: 7.48
P/B: 1.32
EPS next Y Percentage: 8.21%
ROA: -
Short Interest: 3.83M
Perf Year: -
Cash/sh: 8.40
P/C: 1.17
EPS next 5Y: 30.74%
ROE: -
52W Range From: 5.83
52W Range To: 26.25
Perf YTD: 20.27%
Dividend Est.: -
P/FCF: -
EPS past 5Y: -
ROI: -50.21%
52W High: -62.48%
Beta: -
Dividend TTM: -
Quick Ratio: 6.21
Sales past 5Y: -45.00%
Gross Margin: 97.26%
52W Low: 68.95%
ATR (14): 0.90
Dividend Ex-Date: Dec 24, 2019
Current Ratio: 6.21
EPS Y/Y TTM: -
Oper. Margin: -3277.74%
RSI (14): 62.77
Volatility W: 12.03%
Volatility M: 13.10%
Employees: 130
Debt/Eq: 0.00
Sales Y/Y TTM: -
Profit Margin: -3139.74%
Recom: 1.00
Target Price: 31.67
Option/Short: No / Yes
LT Debt/Eq: 0.00
EPS Q/Q: -247.70%
Payout: -
Rel Volume: 0.06
Prev Close: 9.75
Sales Surprise: -
EPS Surprise: -130.10%
Sales Q/Q: -90.00%
Earnings: Feb 26
Avg Volume: 200.12K
Price: 9.85
SMA20: 20.42%
SMA50: 26.82%
SMA200: -17.64%
Trades:
Volume: 643
Change: 1.03%
Technical:
Latest News:
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 million valuation in US IPO somewhat bullish
ZBIO
Summary: Zenas BioPharma aims for a valuation of up to $689.7 million in its U.S. IPO, backed by Bristol-Myers Squibb and targeting to raise $211.7 million by offering 11.76 million shares.
Full article2024-09-06T12:28:43Z